bluebird bio Inc. (NASDAQ: BLUE) is -46.53% lower on its value in year-to-date trading and has touched a low of $2.78 and a high of $8.58 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BLUE stock was last observed hovering at around $3.74 in the last trading session, with the day’s loss setting it -0.04% off its average median price target of $7.00 for the next 12 months. It is also 63.0% off the consensus price target high of $10.00 offered by 13 analysts, but current levels are -23.33% lower than the price target low of $3.00 for the same period.
Currently trading at $3.70, the stock is -10.77% and -5.02% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.59 million and changing -1.07% at the moment leaves the stock -37.24% off its SMA200. BLUE registered 11.11% gain for a year compared to 6-month loss of -46.99%. The firm has a 50-day simple moving average (SMA 50) of $103.35 and a 200-day simple moving average (SMA200) of -$1.73.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a 7.56% gain in the last 1 month and extending the period to 3 months gives it a -31.23%, and is 0.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.58% over the week and 9.70% over the month.
bluebird bio Inc. (BLUE) has around 323 employees, a market worth around $397.90M and $4.00M in sales. Distance from 52-week low is 33.09% and -56.88% from its 52-week high. The company has generated returns on investments over the last 12 months (-146.30%).
bluebird bio Inc. (BLUE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for bluebird bio Inc. (BLUE) is a “Hold”. 13 analysts offering their recommendations for the stock have an average rating of 2.80, where 8 rate it as a Hold and 2 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
bluebird bio Inc. is expected to release its quarterly report on 08/03/2023.The EPS is expected to grow by 58.50% this year.
bluebird bio Inc. (BLUE) Top Institutional Holders
The shares outstanding are 102.92M, and float is at 81.98M with Short Float at 28.73%.
bluebird bio Inc. (BLUE) Insider Activity
A total of 12 insider transactions have happened at bluebird bio Inc. (BLUE) in the last six months, with sales accounting for 6 and purchases happening 6 times. The most recent transaction is an insider sale by Leschly Nick,the company’sDirector. SEC filings show that Leschly Nick sold 4,290 shares of the company’s common stock on Jan 11 at a price of $7.80 per share for a total of $33480.0. Following the sale, the insider now owns 0.28 million shares.
bluebird bio Inc. disclosed in a document filed with the SEC on Jan 11 that Obenshain Andrew (President and CEO) sold a total of 3,178 shares of the company’s common stock. The trade occurred on Jan 11 and was made at $7.80 per share for $24802.0. Following the transaction, the insider now directly holds 0.24 million shares of the BLUE stock.
Still, SEC filings show that on Jan 11, Colvin Richard A (Chief Medical Officer) disposed off 557 shares at an average price of $7.80 for $4347.0. The insider now directly holds 74,231 shares of bluebird bio Inc. (BLUE).
bluebird bio Inc. (BLUE): Who are the competitors?
The company’s main competitors (and peers) include Sangamo Therapeutics Inc. (SGMO) that is trading -63.53% down over the past 12 months and Ionis Pharmaceuticals Inc. (IONS) that is 7.07% higher over the same period. Sanofi (SNY) is 0.52% up on the 1-year trading charts.
